Oct 6 2010
Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that a record date and a special meeting date have been established for Osteotech's stockholders to vote on the proposal to adopt the previously announced merger agreement by and among Osteotech, Medtronic, Inc. ("Medtronic"), Medtronic Sofamor Danek, Inc., a wholly owned direct subsidiary of Medtronic ("MSD"), and England Merger Corporation, a wholly owned direct subsidiary of MSD ("Merger Sub"). The merger agreement provides that Merger Sub will be merged with and into Osteotech, with Osteotech continuing as the surviving corporation, and becoming a wholly owned subsidiary of MSD and a wholly owned indirect subsidiary of Medtronic.
Osteotech stockholders of record at the close of business on October 8, 2010 will be entitled to notice of the special meeting and to vote on the adoption of the merger agreement. The special meeting is scheduled to be held on Tuesday, November 9, 2010 at 9:00 a.m. Eastern Time at Osteotech's corporate office located at 51 James Way, Eatontown, New Jersey. The definitive proxy statement for the special meeting will be filed with the Securities and Exchange Commission and first mailed to stockholders on or about October 14, 2010.